Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11057785 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL5267914 | 1.00 | — | — | |
| SCHEMBL9567841 | 0.96 | — | — | |
| SCHEMBL2214092 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL29066552 | 0.96 | — | — | |
| SCHEMBL3348648 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL1539053 | 0.96 | — | — | |
| SCHEMBL5163464 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL1539055 | 0.96 | — | — | |
| SCHEMBL2214090 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1584621-B1 | A process for the preparation of tolterodine and intermediates thereof | DIPHARMA FRANCIS SRL (IT) | 2007-06-13 | — | — | EP | claimed |
| US-7119212-B2 | Process for the preparation of tolterodine and intermediates thereof | DIPHARMA S.P.A. (IT) | 2006-10-10 | — | — | US | claimed |
| EP-1584621-A1 | A process for the preparation of tolterodine and intermediates thereof | Dipharma S.p.A. (IT) | 2005-10-12 | — | — | EP | claimed |
| US-20050222437-A1 | Process for the preparation of tolterodine and intermediates thereof | DIPHARMA S.P.A. (IT) | 2005-10-06 | — | — | US | claimed |
| JP-2235892-A | — | — | None | — | — | JP | disclosed |
| EP-4419581-B1 | COMPOSITION AND METHOD FOR SYNTHESIS OF AN ALKOXY-FUNCTIONAL ORGANOSILOXANE OLIGOMER | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4419581-A1 | COMPOSITION AND METHOD FOR SYNTHESIS OF AN ALKOXY-FUNCTIONAL ORGANOSILOXANE OLIGOMER | Dow Global Technologies LLC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240228707-A1 | COMPOSITION AND METHOD FOR SYNTHESIS OF AN ALKOXY-FUNCTIONAL ORGANOSILOXANE OLIGOMER | DOW SILICONES CORP (US) | 2024-07-11 | — | — | US | disclosed |
| CN-117186135-A | CS-SA-PNIPAAm@Cu 2+ Application of catalyst in synthesis of chiral organoboron compounds | 湖北工程学院 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023069840-A1 | COMPOSITION AND METHOD FOR SYNTHESIS OF AN ALKOXY-FUNCTIONAL ORGANOSILOXANE OLIGOMER | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-112300121-B | N-aryl substituted carbazole fluorescent probe capable of specifically labeling cell membrane and preparation method thereof | 四川大学华西医院 | 2021-07-13 | — | — | CN | disclosed |
| CN-107771173-B | Preparation of rhodium (III) 2-ethylhexanoate | 优美科股份公司及两合公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20050222437-A1 | Process for the preparation of tolterodine and intermediates thereof | DIPHARMA S.P.A. (IT) | 2005-10-06 | — | — | US | disclosed |
| WO-1994017080-A1 | RHODIUM CATALYZED SILAFORMYLATION OF ALDEHYDES AND PRODUCTS OBTAINED THEREFROM | UTAH STATE UNIVERSITY (US) | 1994-08-04 | — | — | WO | disclosed |
| JP-H02235892-A | KETENE SILYL ACETAL COMPOUND | MITSUBISHI KASEI CORP | 1990-09-18 | — | — | JP | disclosed |
| US-4243824-A | Zero-valent rhodium catalyst hydrogenation | BORG-WARNER CORPORATION (US) | 1981-01-06 | — | — | US | disclosed |
| US-4228312-A | Hydrogenation process | BORG-WARNER CORPORATION (US) | 1980-10-14 | — | — | US | disclosed |
| US-4216331-A | Use of chiral rhodium-diphosphine catalyst capable of catalytic reduction of a tetramisole precursor to give a significant excess of the desired S-(-) isomer levamisole | AMERICAN CYANAMID COMPANY (US) | 1980-08-05 | — | — | US | disclosed |
| US-4207213-A | Zero-valent rhodium catalysts and process of preparation | BORG-WARNER CORPORATION (US) | 1980-06-10 | — | — | US | disclosed |
| US-4166824-A | Chiral rhodium-diphosphine catalyst capable of catalytic reduction of a tetramisole precursor to give a significant excess of the desired S-(-)isomer, levamisole | AMERICAN CYANAMID COMPANY (US) | 1979-09-04 | — | — | US | disclosed |